The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

VOLUME 64 , ISSUE 2 ( April-June, 2022 ) > List of Articles

Original Article

Clinical Profile, Adverse Drug Reaction, and Outcome of Category V Patients at a Drug-resistant Tuberculosis Center, Mumbai

Parikshit Thakare, Ketaki Utpat, Unnati Desai, Jyotsna M Joshi

Keywords : Adverse drug reaction, Category V, Drug-resistant tuberculosis

Citation Information : Thakare P, Utpat K, Desai U, Joshi JM. Clinical Profile, Adverse Drug Reaction, and Outcome of Category V Patients at a Drug-resistant Tuberculosis Center, Mumbai. Indian J Chest Dis Allied Sci 2022; 64 (2):65-67.

DOI: 10.5005/jp-journals-11007-0001

License: CC BY-NC 4.0

Published Online: 08-07-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Abstract

Background: Drug regimens for the treatment of drug-resistant tuberculosis (DR-TB) are composed of salvage drugs to which a patient has never been exposed to previously. Methods: A retrospective observational study was conducted in a DR-TB Center attached to a medical college in a metropolitan city using the database of category V patients (n = 100) who were prediagnosed and referred. The clinical records of the patients were reviewed for demographic data, history, sputum examinations, co-morbidities, and adverse drug reactions (ADRs). The therapy outcomes were assessed as per Revised National Tuberculosis Control Programme (RNTCP) guidelines. Results: Their mean age was 29.1 years; there were 57 males. Mean body weight was 41.8 kg. Pediatric patients (age 12–17) constituted 13%. All the patients had pulmonary TB. Of the 100 cases, 80 were Category IV failure; 5% were defaulters of Category IV; and 15% were treated with second-line drugs adequately in private. Durg-susceptibility test (DST) showed extensively drug-resistant TB (XDR-TB) in 63 and pre-XDR-TB in 37 patients. The outcomes of Category V treatment were cure (7%), died (33%), failed on therapy (4%), transferred out (16%), lost to follow-up (2%), and still on the therapy (35%). Various comorbidities were present in 25% patients. ADRs were seen in 44%, and peripheral neuropathy (18%) was the most commonly observed ADR. Conclusions: DR-TB patients were younger and males were more affected. Mortality of Category V regimen was high (33%). Most common comorbidities were anemia and hypothyroidism. Adverse reactions were common (44%); ADR peripheral neuropathy being the most common.


HTML PDF Share
  1. World Health Organization. Multidrug and extensively drug-resistant TB. Geneva: World Health Organization; 2010.
  2. Sharma S, Kumar S, Saha P, et al. Prevalence of multidrug-resistant tuberculosis among category II pulmonary tuberculosis patients. Indian J Med Res 2011;133:312–315. PMID: 21441686.
  3. Behera D. Drug resistant tuberculosis in India – is it a matter of concern? Indian J Tuber 2007;54(3):105–109. PMID: 17886697.
  4. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004;8(11):1382–1384. PMID: 15581210.
  5. Drobniewski F, Eltringham I, Graham C, et al. A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK. Thorax 2002;57(9):810–816. DOI: 10.1136/thorax.57.9.810.
  6. Michael JS, John TJ. Extensively drug-resistant tuberculosis in India: a review. Indian J Med Res 2012;136(4):599–604. PMID: 23168700.
  7. Friedrich MJ. Tuberculosis update 2017. JAMA 2017;318(23):2287. DOI: 10.1001/jama.2017.18477.
  8. Nene A, Kewalramani N, Agarwal V. Prospective study analysing prevalence of XDR TB in Mumbai, India. Eur Respir J 2016;48:PA2745; DOI: 10.1183/13993003.congress-2016.PA2745.
  9. Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328(8):527–532. DOI: 10.1056/NEJM199302253280802.
  10. Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000;117(3):744–751. DOI: 10.1378/chest.117.3.744.
  11. Daniel O, Osman E, Oladimeji O, et al. Pre-extensive drug resistant tuberculosis (pre-XDR-TB) among MDR-TB patents in Nigeria. Global Adv Res J Microbiol 2013;2(2):22–25.
  12. Dole SS, Waghmare VN, Shaikh AM. Clinical profile and treatment outcome of drug resistant tuberculosis patients of Western Maharashtra, India. J Assoc Physicians India 2017;65(12):18–21. PMID: 31556267.
  13. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. Geneva: World Health Organization; 2008.
  14. Consultation WE. Waist circumference and waist-hip ratio: report of a WHO Expert Consultation. Geneva: World Health Organization; 2008.
  15. Joseph P, Desai VB, Mohan NS, et al. Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India. Indian J Med Res 2011;133(5):529–534. PMID: 21623039.
  16. Lee SW, Kang Y, Yoon YS, et al. The prevalence and evolution of anemia associated with tuberculosis. J Korean Med Sci 2006;21(6):1028–1032. DOI: 10.3346/jkms.2006.21.6.1028.
  17. Shin SS, Hyson AM, Castaneda C, et al. Peripheral neuropathy associated with treatment for multidrug-resistant tuberculosis. Int J Tuber Lung Dis 2003;7(4):347–353. PMID: 12729340.
  18. Tiwari M, Patel M, Shamaliya K. Peripheral neuropathy in XDR-TB patients on second line anti-tubercular therapy. Eur Respir J 2015;46:PA2710; DOI: 10.1183/13993003.congress-2015.PA2710.
  19. Madhav B, Iyer A, Jayalakshmi TK. Side effect profile of 2nd line drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis. Eur Respir J 2015;46:PA2708; DOI: 10.1183/13993003.congress-2015.PA2708.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.